Navigation Links
Interim Safety Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Date:12/27/2007

WESTMINSTER, Colo., Dec. 27 /PRNewswire-FirstCall/ -- Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that an independent Data Monitoring Committee (DMC) has completed the pre-specified 65-patient safety review of data from the Company's pivotal Phase 2 PROPEL trial of PDX (pralatrexate) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL), and has recommended that the trial continue per the protocol. This interim assessment was based upon an evaluation of patients enrolled in the study who completed at least one cycle of treatment with PDX. The Company currently expects to complete patient enrollment in the PROPEL study in the second quarter of 2008.

"The DMC recommendation represents another important milestone in the development of a potential new treatment option for patients with relapsed or refractory peripheral T-cell lymphoma, a patient population for which there are currently no approved agents," said Pablo J. Cagnoni, M.D., Senior Vice President and Chief Medical Officer of Allos. "We remain pleased with the progress of the PROPEL trial and look forward to continuing to drive our PDX product development and commercialization plans in 2008."

PROPEL (Pralatrexate in Patients with Relapsed Or Refractory PEripheral T-cell Lymphoma) is a pivotal Phase 2, international, multi-center, open-label, single-arm study that will seek to enroll a minimum of 100 evaluable patients with relapsed or refractory PTCL who have progressed after at least one prior treatment. Patients receive 30 mg/m2 of PDX once every week for six weeks followed by one week of rest per cycle of treatment. The primary efficacy endpoint of the study is objective response rate (complete and partial response). Secondary efficacy
'/>"/>

SOURCE Allos Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. Interim Response and Safety Analyses Support Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-Cell Lymphoma
3. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
4. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
5. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
6. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
7. Grantees of the Avon Foundation Breast Cancer Prevention Research Initiative Gather in Houston to Report Interim Findings
8. Novavax Announces Favorable Interim Results from Human Clinical Trial for Its Pandemic Influenza Vaccine Program
9. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
10. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
11. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... BURLINGTON, Mass. , Sept. 30, 2014  Decision ... (PV) devices in Brazil , ... and China (BRIC) will see ... techniques are increasingly favored over surgical procedures. Although revenues ... care resources, reimbursement challenges, prolonged device approval times and ...
(Date:9/30/2014)... September 30, 2014 ... the "Glycobiology/Glycomics Market by Product [Enzymes (Glycosyltransferase, Neuraminidase, ... and Reagents], Application (Immunology, Oncology) & by ... published by MarketsandMarkets, provides a detailed overview ... current market trends, and strategies impacting the ...
(Date:9/30/2014)... LEXINGTON, Ky. , Sept. 30, 2014 ... coherence tomography (OCT), offered a new look at the ... to alter how physicians understand and treat the disease, ... study, conducted at Baptist Health Lexington between September 2010 ... issue of the Journal of the American College ...
Breaking Medicine Technology:Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 2Brazilian, Russian, Indian and Chinese Markets for Peripheral Vascular Devices Will See Strong Expansion Through 2023 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 2Glycobiology / Glycomics Market Worth $928.11 Million by 2019 3Glycobiology / Glycomics Market Worth $928.11 Million by 2019 4New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... , , VENLO, Netherlands , Feb. 2 QIAGEN N.V. ... financial results call. The Webcast will take place at 9:30 a.m. EST on ... President and Chief Executive Officer, and Roland Sackers, Chief Financial Officer. , ... QIAGEN,s fourth quarter and year-end 2009 financial , ...
... , JERUSALEM , Feb. ... ) announced today the availability of new resources to support ... to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand ... due to inadequate secretion of normal endogenous growth hormone. The ...
Cached Medicine Technology:Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 2Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Quarter and Year-End 2009 Financial Results Call Set for February 9 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 2Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 3Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 4Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 5Teva's Needle-Free Tjet(R) Device Takes a Kid-Friendly Approach to Growth Hormone Deficiency Treatment 6
(Date:10/1/2014)... This October, Request A Test , a leading ... 10% off all testing for Diabetes . Customers ... save. The Center for Disease Control (CDC) reports that ... Diabetes. Because many people do not display symptoms, it ... serious health problems. Blood testing can help a person ...
(Date:10/1/2014)... October 01, 2014 After a run ... "Beautiful Births", emerging filmmaker Jacqui Blue is continuing her ... discover the truth about natural birth. The documentary has ... over the world and has been an effective medium ... the topics highlighted in the film provide a wealth ...
(Date:10/1/2014)... 01, 2014 The Oliver Law ... new Other-Sonic Ultrasound Gel lawsuit web page ... the litigation surrounding the 2011 Pseudomonas aeruginosa / ... Royal Oak, Michigan, which was ultimately traced to ... representing William Beaumont patients who allegedly became ill ...
(Date:10/1/2014)... October 01, 2014 Indosoft, Inc., a leading ... announces that it has added support for Sangoma Lyra ... and Indosoft have a history of bringing innovative ... patent-pending technology offers a significant benefit to those using Asterisk ... is now available to users of Q-Suite. , In the ...
(Date:10/1/2014)... 01, 2014 The annual Social Security cost-of-living ... 2015, says a new forecast by The Senior Citizens ... price index (CPI) data through August, TSCL forecasts that COLAs ... the sixth consecutive year of record low COLAs,” states TSCL ... became automatic in 1975,” he notes. , Over the past ...
Breaking Medicine News(10 mins):Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 2Health News:Request A Test Offers 10% off Diabetes Testing in October 2014 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 2Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 3Health News:Filmmaker Jacqui Blue's Beautiful Births Documentary, "Really Touched My Heart" 4Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 2Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 3Health News:Other-Sonic Ultrasound Gel Lawsuit Page Launched by The Oliver Law Group P.C. To Provide Information On Pseudomonas Outbreak Linked to Recalled Ultrasound Gel 4Health News:Indosoft Announces Q-Suite Support For Sangoma Lyra 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 2Health News:The Senior Citizens League (TSCL) Says Sixth Consecutive Year Of Record Low COLAs “Unprecedented” 3
... , TUESDAY, Jan. 24 (HealthDay News) -- People without ... medical care or prescription drugs than people with jobs who ... the depths of the recent recession, unemployment reached 9.6 percent, ... access to care and most people rely on getting insured ...
... , TUESDAY, Jan. 24 (HealthDay News) -- Children with ... gastroesophageal reflux don,t get additional asthma control from acid-reducing ... these medications when there are no digestive issues increases ... the study. "There,s a strong epidemiological link between ...
... , TUESDAY, Jan. 24 (HealthDay News) -- If you have ... of painful flare-ups, new research suggests. The new study ... in the previous four months. They were divided into three ... or skim milk powder enriched with glycomacropeptide (GMP) and G600 ...
... from Rhode Island Hospital reports on the impact to ... upcoming revision to the Diagnostic and Statistical Manual, 5th ... these changes could result in false-negative diagnoses for patients. ... Clinical Psychiatry and is now available online in ...
... announce that it has entered a new long-term collaboration with ... journal Alcohol and Alcoholism . At the end ... the journal Alcohol and Alcoholism , which was previously ... founded in 1967 to improve the understanding and management of ...
... German . Studies currently available provide ... be detected and treated earlier, and consequently tumours occur less ... In this context, an HPV test can be used alone ... both screening procedures also carry a risk of harm in ...
Cached Medicine News:Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 2Health News:Even With Insurance, Unemployed Have Worse Health Outcomes 3Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 2Health News:Heartburn Meds Won't Help, May Harm Kids With Asthma 3Health News:Enriched Skim Milk Good for Gout, Study Suggests 2Health News:The impact of deleting 5 personality disorders in the new DSM-5 2Health News:Oxford University Press and Medical Council on Alcohol announce long-term partnership 2Health News:HPV testing: Indications of a benefit in primary screening 2Health News:HPV testing: Indications of a benefit in primary screening 3Health News:HPV testing: Indications of a benefit in primary screening 4
... The National Laboratory Training Network (NLTN) ... Association of Public Health Laboratories (APHL) and ... (CDC). NLTN provides cost-effective training in a ... resources, including a FREE Lending Library. Log ...
... The AAFP-PT Laboratory Proficiency Testing and ... programs are designed to assist POLs, clinics ... are designed to assure accuracy of patient ... regulatory requirements. Participation provides the opportunity to ...
An indirect immunofluorescence (IFA) antibody test for the detection and semiquantitation of anti-glomerular basement membrane (GBM) antibodies in human serum. Slide Detail: 6-well Monkey Kidney Subs...
An enzyme linked immunosorbant assay (ELISA) for the detection and quantitation of Rheumatoid Factor (RF) of IgM isotype in human serum....
Medicine Products: